Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

Production at the facility in Shanghai is expected to be near 100% starting on June 6.

Gadolinium might be an alternative, stop-gap solution for interventional procedures during the current iodine contrast shortage.

Kirk Garratt, MD, medical director of the Center for Heart and Vascular Health, ChristianaCare, and a past president of SCAI, explains what this shortage means for interventional cardiologists.

The COVID lockdowns at the Shanghai plant began on March 31, and although the plant there has since resumed operations, they are not yet at 100% capacity.

Terry Bowers, MD, director of vascular medicine at Beaumont Hospital and national co-chair of the Pulmonary Embolism Research Collaborative (PERC), explains the trend toward creating pulmonary embolism (PE) response teams that include cardiology. 

The virtual reality training sessions were designed to feature "the same sights, sound and sensations a surgeon would encounter during real procedures." 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.